Penny Stocks To Buy [Or Avoid] #1 Conatus Pharmaceuticals
Last but not least, it is Conatus Pharmaceuticals (CNAT – Free Report) that could generate some attention from investors. Towards the end of January, the company announced that it reached a definitive agreement with regards to a merger with the privately held company Histogen Inc. It is going to be merged with a Conatus subsidiary, and the entire deal is going to be conducted in stock.
Furthermore, according to the company, the combined entity will operate under the name ” Histogen Inc. “. After closing, the combined company is expected to change its trading symbol to “HSTO”.
This week the company presents at the BIO CEO & Investor Conference. If CNAT stock is one you’re watching, mark February 11 in your calendar. Richard Pascoe, Charman, and CEO of Histogen will give an overview of the company’s technology and development pipeline.
